Position history for FARALLON CAPITAL MANAGEMENT LLC's holdings in CRINETICS PHARMACEUTICALS IN
FARALLON CAPITAL MANAGEMENT LLC holds 6.9M shares of CRNX (CRINETICS PHARMACEUTICALS IN), worth $322.7M as of 2025-Q4. The position was increased (++20.2% shares). CRNX represents 1.5% of FARALLON CAPITAL MANAGEMENT LLC's portfolio.
Current Value
$322.7M
Current Shares
6.9M
Total Value Change
+$300.5M
Total Shares Change
+6.4M
Other major holders of CRNX: BNP PARIBAS FINANCIAL MARKETS, FMR LLC, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Increased |
| 6.9M |
+20.2% |
| $322.7M |
| 1.5% |
| $47.39 |
58 |
| 2025-Q3 | Increased | 5.8M | +24.2% | $240.3M | 1.0% | $43.51 | 53 |
| 2025-Q2 | Increased | 4.6M | +0.9% | $133.6M | 0.6% | $29.96 | 43 |
| 2025-Q1 | Increased | 4.6M | +13.0% | $154.5M | 0.9% | $34.73 | 48 |
| 2024-Q4 | Increased | 4.1M | +250.7% | $208.4M | 1.1% | $50.67 | 78 |
| 2024-Q3 | Increased | 1.2M | +133.8% | $59.4M | 0.3% | $50.75 | 57 |
| 2024-Q2 | Increased | 497,000 | +9840.0% | $22.3M | 0.1% | $44.79 | 55 |